ProMIS Neurosciences Announces July 28 Webinar To Discuss Six-Month Blinded Interim Data From PMN310 PRECISE-AD Phase 1b Trial In Early Alzheimer's

Benzinga Newsdesk www.benzinga.com Neutral 88.4%